Damora Therapeutics, Inc.

DMRAReported to SECin USCIK 0001800315Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5
Form 4 lines at Damora Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Jarrett JenniferDirector, President and CEOOpen-market buy$252,87512,500 sharesSep 28, 2026Jarrett JenniferDirector, President and CEO$252,875Buy · Sep 28Open-market buy12,500Sep 28, 2026
Cheng Andrew—Awardnothing paid30,350 sharesAug 13, 2026Cheng Andrewnothing paidAward · Aug 13Award30,350Aug 13, 2026
Winslow GarrettGeneral CounselOption exercisenothing paid680 sharesJul 7, 2026Winslow GarrettGeneral Counselnothing paidExercise · Jul 7Option exercise680Jul 7, 2026
Winslow GarrettGeneral CounselOpen-market sell$7,345245 sharesJul 7, 2026Winslow GarrettGeneral Counsel$7,345Sell · Jul 7Open-market sell245Jul 7, 2026
Winslow GarrettGeneral CounselOption exercise—680 sharesJul 7, 2026Winslow GarrettGeneral Counsel—Exercise · Jul 7Option exercise680Jul 7, 2026